The Arg16Gly-β(2)-adrenoceptor single nucleotide polymorphism: exercise capacity and survival in patients with end-stage heart failure.
Heart failure (HF) is characterized by impaired myocardial β-adrenergic signal transduction. Single nucleotide polymorphisms (SNPs) within the β(1)- (Ser49Gly, Arg389Gly) and β(2)-adrenoceptor (Arg16Gly, Gln27Glu, Thr164Ile) have been associated with alterations in adrenoceptor (AR) function sensitivity in vitro and in vivo and possibly contribute to HF progression. The present study evaluated the relation of those SNPs to morbidity and mortality in patients with end-stage HF. A total of 226 patients with end-stage HF (ejection fraction ≤35%) were genotyped for the two β(1)AR SNPs and the three β(2)AR SNPs. Outcome (death, heart transplantation (HTX)) was determined from May 2003 to June 2004. Heart rate, systolic and diastolic blood pressure, and peak oxygen uptake were measured during graded treadmill exercise. Left ventricular end-diastolic and end-systolic diameters, ejection fraction, and fractional shortening at rest were measured using two-dimensional echocardiography. Minor allele frequencies were 0.12 for Gly49 and 0.27 for Gly389 (β(1)AR) and 0.37 for Arg16, 0.43 for Glu27 and 0.01 for Ile164 (β(2)AR). During follow-up, 45 patients died (20%), and 27 patients underwent HTX (12%). No significant differences in the incidence or in the time-to-endpoint of death and HTX between genotypes of the different SNPs within the β(1)- and β(2)AR were detected. However, patients carrying the Arg16-β(2)AR tended to have lower exercise capacity and a higher probability for death/HTX within 45 months (survival proportion 46%) than patients carrying the Gly16Gly-β(2)AR (survival proportion 64%). In conclusion, the Arg16Gly-β(2)AR might impact on exercise capacity and outcome in end-stage heart failure.
Leineweber
Kirsten
K
Institute for Pathophysiology, University of Duisburg-Essen School of Medicine, Essen, Germany.
Frey
Ulrich H
UH
Tenderich
Gero
G
Toliat
Mohammad Reza
MR
Zittermann
Armin
A
Nürnberg
Peter
P
Körfer
Reiner
R
Siffert
Winfried
W
Heusch
Gerd
G
D001794:Blood Pressure / Q000502:physiology; D018450:Disease Progression; D004452:Echocardiography; D005080:Exercise Test; D005260:Female; D005838:Genotype; D006333:Heart Failure / Q000235:genetics* / Q000401:mortality* / Q000503:physiopathology / Q000601:surgery; D006339:Heart Rate / Q000502:physiology; D016027:Heart Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000502:physiology; D005082:Physical Exertion / Q000502:physiology*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics*; D016896:Treatment Outcome
D018343:Receptors, Adrenergic, beta-2
Pharmacol Rev. 1999 Dec;51(4):651-90
10581327
J Biol Chem. 2003 Mar 21;278(12):10784-9
12525504
Expert Opin Pharmacother. 2007 Dec;8(18):3195-203
18035963
J Appl Physiol (1985). 2006 Feb;100(2):507-11
16210433
J Card Fail. 1996 Dec;2(4 Suppl):S35-43
8951559
Naunyn Schmiedebergs Arch Pharmacol. 2003 Jan;367(1):10-21
12616336
J Am Soc Echocardiogr. 2007 Mar;20(3):290-7
17336757
Life Sci. 2004 Apr 23;74(23):2803-14
15072081
Eur J Pharmacol. 2001 Jun 15;421(3):141-7
11516429
Chest. 1988 Nov;94(5):931-8
3180897
Pharmacogenetics. 2001 Apr;11(3):191-7
11337934
Pharmacogenetics. 2004 Nov;14(11):711-6
15564877
Int J Obes Relat Metab Disord. 2001 Nov;25(11):1599-603
11753577
J Am Coll Cardiol. 2007 Jan 16;49(2):274-6
17222742
J Card Fail. 2009 Jun;15(5):435-41
19477404
Am J Cardiol. 2007 Jan 15;99(2):250-5
17223428
Circ Res. 2003 Nov 14;93(10):896-906
14615493
Biochemistry. 1994 Aug 16;33(32):9414-9
7915137
Nat Med. 2003 Oct;9(10):1300-5
14502278
Br J Pharmacol. 2009 Sep;158(1):61-9
19422376
J Appl Physiol (1985). 2005 Nov;99(5):1776-81
15994241
N Engl J Med. 2002 Mar 14;346(11):793-801
11893790
J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5
16325050
J Am Coll Cardiol. 2008 Aug 19;52(8):644-51
18702968
Clin Pharmacol Ther. 2005 Sep;78(3):232-8
16153394
Clin Pharmacol Ther. 2003 Oct;74(4):372-9
14534524
N Engl J Med. 2001 Oct 4;345(14):1030-5
11586955
Hypertension. 2000 Sep;36(3):371-5
10988267
Naunyn Schmiedebergs Arch Pharmacol. 2007 Jul;375(5):303-9
17541557
J Physiol. 2003 Jan 15;546(Pt 2):583-9
12527744
Eur J Heart Fail. 2003 Aug;5(4):463-8
12921807
Eur J Heart Fail. 2005 Oct;7(6):966-73
16227135
J Biol Chem. 1999 Apr 30;274(18):12670-4
10212248
Eur J Heart Fail. 2008 Jan;10(1):3-13
18158268
Clin Pharmacol Ther. 2005 Sep;78(3):221-31
16153393
Eur Heart J. 2000 Nov;21(22):1853-8
11052857
Basic Res Cardiol. 2001 Nov;96(6):528-38
11770070
Eur Heart J. 2006 Apr;27(7):808-16
16421173
Nat Clin Pract Cardiovasc Med. 2005 Sep;2(9):475-83
16265588
Am J Med. 2004 Oct 1;117(7):451-8
15464701
Recept Channels. 2003;9(5):315-23
14527875
Br J Pharmacol. 2004 May;142(1):51-6
15037517
J Biol Chem. 2002 Aug 23;277(34):30429-35
12034720
Pharmacol Rev. 1991 Jun;43(2):203-42
1677200
Br J Pharmacol. 2003 Jan;138(2):386-92
12540530
J Biol Chem. 1993 Nov 5;268(31):23116-21
7901205
Eur J Pharmacol. 2004 Oct 1;500(1-3):167-76
15464030
Chest. 2006 Nov;130(5):1527-34
17099033
J Am Coll Cardiol. 2002 Oct 2;40(7):1275-82
12383575
Pharmacogenet Genomics. 2006 Jan;16(1):9-13
16344717
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288-93
16844790
J Cardiovasc Pharmacol. 2002 Feb;39(2):155-60
11791000
Pharmacogenetics. 2001 Apr;11(3):199-205
11337935
Clin Pharmacol Ther. 2003 Apr;73(4):366-71
12709726
Am J Cardiol. 2008 Sep 15;102(6):726-32
18773997
Basic Res Cardiol. 1996;91 Suppl 2:29-34
8957541
Pharmacol Ther. 2008 Jan;117(1):1-29
17916379
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):1-22
14647973